| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer.
|
Lab Invest
|
2002
|
1.57
|
|
2
|
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.
|
Am J Pathol
|
2009
|
1.54
|
|
3
|
Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
|
J Clin Invest
|
2007
|
1.47
|
|
4
|
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer.
|
Clin Cancer Res
|
2002
|
1.44
|
|
5
|
Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis.
|
Am J Pathol
|
2004
|
1.42
|
|
6
|
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
|
Cancer Res
|
2003
|
1.41
|
|
7
|
Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
|
Clin Cancer Res
|
2007
|
1.30
|
|
8
|
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
|
Int J Cancer
|
2007
|
1.30
|
|
9
|
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
|
Mol Cancer Ther
|
2007
|
1.29
|
|
10
|
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
|
Mol Cancer Ther
|
2011
|
1.26
|
|
11
|
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells.
|
Cancer Res
|
2004
|
1.22
|
|
12
|
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways.
|
Cancer Res
|
2003
|
1.17
|
|
13
|
Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma.
|
Cancer
|
2003
|
1.16
|
|
14
|
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.
|
BMC Cancer
|
2010
|
1.12
|
|
15
|
Biology of angiogenesis in tumors of the gastrointestinal tract.
|
Microsc Res Tech
|
2003
|
1.11
|
|
16
|
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
|
Eur J Cancer
|
2008
|
1.10
|
|
17
|
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
|
Mol Cancer Ther
|
2004
|
1.09
|
|
18
|
Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells.
|
Cytokine
|
2002
|
1.07
|
|
19
|
The role of the microenvironment and intercellular cross-talk in tumor angiogenesis.
|
Semin Cancer Biol
|
2002
|
1.06
|
|
20
|
Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
|
Anticancer Res
|
2009
|
1.05
|
|
21
|
Role of angiogenesis in the development and growth of liver metastasis.
|
Ann Surg Oncol
|
2002
|
1.01
|
|
22
|
Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF.
|
Cytokine
|
2005
|
0.99
|
|
23
|
Interleukin-1beta regulates angiopoietin-1 expression in human endothelial cells.
|
Cancer Res
|
2004
|
0.98
|
|
24
|
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells.
|
Biochim Biophys Acta
|
2010
|
0.95
|
|
25
|
No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury.
|
Stem Cells
|
2006
|
0.94
|
|
26
|
Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.
|
Hepatology
|
2009
|
0.94
|
|
27
|
ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
|
BMC Cancer
|
2008
|
0.94
|
|
28
|
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
|
Mol Cancer Ther
|
2008
|
0.93
|
|
29
|
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
|
Mol Cancer Ther
|
2007
|
0.92
|
|
30
|
Vascular endothelial growth factor receptors: expression and function in solid tumors.
|
Clin Adv Hematol Oncol
|
2004
|
0.92
|
|
31
|
Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.
|
Cancer Res
|
2003
|
0.91
|
|
32
|
Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
|
Anticancer Res
|
2012
|
0.90
|
|
33
|
Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha.
|
Mol Cancer Res
|
2009
|
0.90
|
|
34
|
Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany.
|
Int J Clin Exp Med
|
2010
|
0.86
|
|
35
|
Promises and pitfalls of anti-angiogenic therapy in clinical trials.
|
Trends Mol Med
|
2003
|
0.86
|
|
36
|
Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: a molecular target for anti-angiogenic therapy?
|
Curr Cancer Drug Targets
|
2010
|
0.85
|
|
37
|
STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.
|
Neoplasia
|
2012
|
0.85
|
|
38
|
Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models.
|
Surgery
|
2009
|
0.83
|
|
39
|
Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability.
|
Transplantation
|
2007
|
0.82
|
|
40
|
Dual-targeting of mTOR and HSP90 for cancer therapy: facing oncogenic feed-back-loops and acquired mTOR resistance.
|
Cell Cycle
|
2010
|
0.81
|
|
41
|
Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.
|
Exp Hematol
|
2007
|
0.81
|
|
42
|
Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.
|
Langenbecks Arch Surg
|
2008
|
0.79
|
|
43
|
Antiangiogenic therapy targeting factors that enhance endothelial cell survival.
|
Semin Oncol
|
2002
|
0.79
|
|
44
|
Synopsis of angiogenesis inhibitors in oncology.
|
Oncology (Williston Park)
|
2002
|
0.78
|
|
45
|
Angiopoietins and their role in colon cancer angiogenesis.
|
Oncology (Williston Park)
|
2002
|
0.78
|
|
46
|
EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells.
|
Int J Oncol
|
2013
|
0.78
|
|
47
|
Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors.
|
Anticancer Res
|
2012
|
0.77
|
|
48
|
The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.
|
Clin Colorectal Cancer
|
2007
|
0.76
|
|
49
|
Drug abuse, personality disorder, and colorectal metastases: when chemotherapy becomes an illusion and surgery cannot help any more.
|
Int J Colorectal Dis
|
2010
|
0.75
|